EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET

Romain-David Seban

Journal of Nuclear Medicine · 2023

DOI: 10.2967/jnumed.123.266490 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Romain-David Seban. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

REPLY: I extend my gratitude to Altena et al. for their insightful response to our letter to the editor ([1][1]) regarding human epidermal growth factor receptor 2 (HER2)–targeted PET imaging in breast cancer patients. It is with great enthusiasm that I acknowledge the pivotal role their work

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemalePositron Emission Tomography Computed TomographyPositron-Emission TomographyErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18

Substanzen

Erb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18

Zitieren

APA

Seban, R. D. (2023). Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266490

Vancouver

Seban RD. Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.266490

BibTeX
@article{Seban2023,
  author = {Seban, Romain-David},
  title = {Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  doi = {10.2967/jnumed.123.266490}
}
Kostenlos starten →